Bio-Path Holdings, Inc.
NASDAQ Capital Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Peter H. Nielsen MBA
- Full Time Employees
- 10
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4710 Bellaire Boulevard Bellaire TX United States of America 77401
- IPO Date
- Mar 4, 2008
- CIK
- 0001133818
- Website
- biopathholdings.com
- Similar Companies
- Business
- Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Company News
All You Need to Know About Bio-Path (BPTH) Rating Upgrade to Buy
Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Bio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call Transcript
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
Bio-Path Holdings Reports Second Quarter 2024 Financial Results
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
Bio-Path Holdings Provides Clinical Update and Expansion Plans
Why Is Bio-Path (BPTH) Stock Up 20% Today?
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress